These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 36244997

  • 1. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
    Retnakaran R, Ye C, Emery A, Kramer CK, Zinman B.
    Nat Commun; 2022 Oct 16; 13(1):6109. PubMed ID: 36244997
    [Abstract] [Full Text] [Related]

  • 2. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
    Retnakaran R, Pu J, Ye C, Emery A, Kramer CK, Zinman B.
    Cardiovasc Diabetol; 2023 Mar 09; 22(1):50. PubMed ID: 36894921
    [Abstract] [Full Text] [Related]

  • 3. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, 4B Study Group.
    Diabetes Care; 2014 Oct 09; 37(10):2763-73. PubMed ID: 25011946
    [Abstract] [Full Text] [Related]

  • 4. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
    de Lapertosa SB, Frechtel G, Hardy E, Sauque-Reyna L.
    Diabetes Res Clin Pract; 2016 Dec 09; 122():38-45. PubMed ID: 27776251
    [Abstract] [Full Text] [Related]

  • 5. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
    Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, Fernández Landó L, Patel H.
    JAMA; 2023 Nov 07; 330(17):1631-1640. PubMed ID: 37786396
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
    Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Järvinen H, Diamant M.
    Diabetes Care; 2011 Sep 07; 34(9):2041-7. PubMed ID: 21868779
    [Abstract] [Full Text] [Related]

  • 9. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, Bekiari E, Matthews DR, Tsapas A.
    Ann Intern Med; 2018 Aug 07; 169(3):165-174. PubMed ID: 29987326
    [Abstract] [Full Text] [Related]

  • 10. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF, Blevins TC, Wise JK, Liljenquist DR, Jiang HH, Jacobson JG, Martin SA, Jackson JA.
    Diabetes Obes Metab; 2014 Jun 07; 16(6):510-8. PubMed ID: 24298995
    [Abstract] [Full Text] [Related]

  • 11. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T, Pfohl M, Forst T, Pscherer S, Bramlage P, Foersch J, Borck A, Seufert J.
    Diabetes Metab Syndr; 2017 Jun 07; 11(1):51-57. PubMed ID: 27578616
    [Abstract] [Full Text] [Related]

  • 12. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB.
    Diabetes Care; 2003 Mar 07; 26(3):799-804. PubMed ID: 12610040
    [Abstract] [Full Text] [Related]

  • 13. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V, Cleall S, Pontiroli AE, Giugliano D.
    Diabetes Obes Metab; 2011 Dec 07; 13(12):1149-57. PubMed ID: 21819517
    [Abstract] [Full Text] [Related]

  • 14. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL.
    Clin Ther; 2010 May 07; 32(5):896-908. PubMed ID: 20685497
    [Abstract] [Full Text] [Related]

  • 15. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 16. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
    Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C.
    Diabetes Care; 2010 Jul 18; 33(7):1509-15. PubMed ID: 20357372
    [Abstract] [Full Text] [Related]

  • 17. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
    Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA.
    Diabetes Care; 2009 Jun 18; 32(6):1007-13. PubMed ID: 19336625
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.
    Clin Ther; 2012 Sep 18; 34(9):1892-908.e1. PubMed ID: 22884767
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA, Mersey JH, Zhou S, Bromberger LA.
    Endocr Pract; 2012 Sep 18; 18(1):17-25. PubMed ID: 21742605
    [Abstract] [Full Text] [Related]

  • 20. Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.
    Retnakaran R, Pu J, Emery A, Kramer CK, Zinman B.
    Diabetes Obes Metab; 2023 Sep 18; 25(9):2473-2481. PubMed ID: 37380623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.